GuiZhou SanLi Pharmaceutical Co.,Ltd

Shanghai Stock Exchange 603439.SS

GuiZhou SanLi Pharmaceutical Co.,Ltd Net Income Margin for the year ending December 31, 2023: 17.90%

GuiZhou SanLi Pharmaceutical Co.,Ltd Net Income Margin is 17.90% for the year ending December 31, 2023, a 6.85% change year over year. Net Income Ratio, also known as the profit margin, is the ratio of net income to net sales, showing the percentage of revenue that remains as profit after all expenses are deducted.

GuiZhou SanLi Pharmaceutical Co.,Ltd Net Income Margin for the year ending December 31, 2022 was 16.76%, a 3.31% change year over year.
GuiZhou SanLi Pharmaceutical Co.,Ltd Net Income Margin for the year ending December 31, 2021 was 16.22%, a 8.79% change year over year.
GuiZhou SanLi Pharmaceutical Co.,Ltd Net Income Margin for the year ending December 31, 2020 was 14.91%, a -1.00% change year over year.
GuiZhou SanLi Pharmaceutical Co.,Ltd Net Income Margin for the year ending December 31, 2019 was 15.06%, a -1.55% change year over year.

Key data

Date	Net Income Margin	EBITDA Margin	EBIT Margin	EBITDA

Shanghai Stock Exchange: 603439.SS

GuiZhou SanLi Pharmaceutical Co.,Ltd

CEO	Mr. Hai Zhang
IPO Date	April 28, 2020
Location	China
Headquarters	Xiayun Industrial Park
Employees	2,282
Sector	Health Care
Industries Pharmaceuticals

Description

GuiZhou SanLi Pharmaceutical Co.,LTD. engages in the research and development, production, and marketing of pharmaceutical products. It offers pediatric medication, respiratory system medication, cardiovascular and cerebrovascular drugs, digestive medicine, trauma injury medication, rehabilitation medicine, and ophthalmic medicine. The company was founded in 1995 and is based in Guiyang, China.

Key trends

Past 5 years